Acute, Noncardiac Mortality Risk Up for CA Patients With STEMI

Share this content:
Acute, Noncardiac Mortality Risk Up for CA Patients With STEMI
Acute, Noncardiac Mortality Risk Up for CA Patients With STEMI

FRIDAY, Dec. 2, 2016 (HealthDay News) -- Cancer survivors with ST-segment elevation myocardial infarction (STEMI) have increased acute in-hospital and long-term noncardiac mortality risk but no increased acute or long-term cardiac mortality risk with guideline-recommended cardiac care, according to a study published in the December issue of the Mayo Clinic Proceedings.

Researchers at the Mayo Clinic in Rochester, Minn., reviewed data on 2,346 patients with STEMI undergoing primary percutaneous coronary intervention. One in 10 had a history of cancer.

Cancer survivors did not have a higher risk of STEMI-related mortality; however, they were more than three times more likely to die of non-heart-related causes. After their STEMI, patients with a history of cancer were more likely to arrive at the hospital with cardiogenic shock. These patients were also more likely to receive intra-aortic balloon pump therapy. Cancer survivors were also more likely to be hospitalized for heart failure during follow-up. But those who received proper medical treatment were not at increased risk of dying from cardiovascular disease.

"This study supports the importance of cardiologists and oncologists working together to care for these patients," senior author Joerg Herrmann, M.D., an interventional cardiologist at the clinic, said in a statement.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »